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Hedgehog Inhibition Promotes a Switch from Type II to
Type I Cell Death Receptor Signaling in Cancer Cells
Satoshi Kurita1, Justin L. Mott1, Sophie C. Cazanave1, Christian D. Fingas1, Maria E. Guicciardi1, Steve F.
Bronk1, Lewis R. Roberts1, Martin E. Fernandez-Zapico1,2, Gregory J. Gores1*
1 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America, 2 Division of Oncology Research, Schulze Center for Novel
Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America

Abstract
TRAIL is a promising therapeutic agent for human malignancies. TRAIL often requires mitochondrial dysfunction, referred to
as the Type II death receptor pathway, to promote cytotoxicity. However, numerous malignant cells are TRAIL resistant due
to inhibition of this mitochondrial pathway. Using cholangiocarcinoma cells as a model of TRAIL resistance, we found that
Hedgehog signaling blockade sensitized these cancer cells to TRAIL cytotoxicity independent of mitochondrial dysfunction,
referred to as Type I death receptor signaling. This switch in TRAIL requirement from Type II to Type I death receptor
signaling was demonstrated by the lack of functional dependence on Bid/Bim and Bax/Bak, proapoptotic components of
the mitochondrial pathway. Hedgehog signaling modulated expression of X-linked inhibitor of apoptosis (XIAP), which
serves to repress the Type I death receptor pathway. siRNA targeted knockdown of XIAP mimics sensitization to
mitochondria-independent TRAIL killing achieved by Hedgehog inhibition. Regulation of XIAP expression by Hedgehog
signaling is mediated by the glioma-associated oncogene 2 (GLI2), a downstream transcription factor of Hedgehog. In
conclusion, these data provide additional mechanisms modulating cell death by TRAIL and suggest Hedgehog inhibition as
a therapeutic approach for TRAIL-resistant neoplasms.
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apoptosis [7,8]; the dependence on mitochondrial dysfunction for
cell death is referred as the Type II death receptor pathway of
apoptosis [6]. Type I death receptor signaling appears to be
regulated at the level of caspase-3 activation, whereas Type II
death receptor signaling is regulated at the level of mitochondria
by members of the antiapoptotic Bcl-2 protein family [7,8,9,10].
TRAIL usually signals through the Type II, mitochondriadependent pathway [11], a pathway which is frequently inhibited
in cancers resulting in TRAIL resistance [12,13].
Herein, we demonstrate that inhibition of the oncogenic
Hedgehog pathway represses the expression of XIAP and
sensitizes cancer cells to TRAIL cytotoxicity, using cholangiocarcinoma cells as a model to study TRAIL resistance. These cancer
cells abundantly express antiapoptotic Bcl-2 family proteins,
especially Mcl-1, which mediates TRAIL resistance [14,15].
Mcl-1 inhibition of the mitochondrial pathway of cell death is
especially relevant to cholangiocarcinoma cells as they paradoxically express TRAIL in vivo, and likely must continuously
circumvent TRAIL cytotoxic signaling for survival [16]. Given
the emerging data implicating oncogenic Hedgehog signaling in
gastrointestinal tumor biology [17,18], we explored Hedgehog
signaling as a mechanism contributing to TRAIL resistance by
cancer cells. We previously reported that the Hedgehog pathway is
constitutively active in these cells and that its inhibition sensitizes
cholangiocarcinoma cells to TRAIL cytotoxicity coinciding with
up-regulation of TRAIL receptor DR4 [19]. However, it was

Introduction
Tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL), a potent death ligand that preferentially induces
apoptosis in transformed cells, initiates signaling cascades by
ligating two death receptors, DR4 (TNFRSF10A, also referred to
as TRAIL receptor 1) and DR5 (TNFRSF10B, also referred to as
TRAIL receptor 2/KILLER/TRICK-2) [1]. TRAIL-induced
clustering and oligomerization of DR4 and DR5 results in
conformational changes of the death domains within their
cytoplasmic tails, facilitating recruitment and activation of caspases
8 and 10 within a death inducing signaling complex (DISC)
[2,3,4]. If activation of these initiator caspases is sufficiently robust,
they directly activate caspase 3, which in turn results in cellular
demise by the so-called Type I death receptor pathway of
apoptosis [5,6]. However, if the magnitude of caspase 8 and 10
activation is not sufficient to directly activate caspase 3, TRAIL
may still induce apoptosis through cleavage of the proapoptotic
BH3-only protein Bid to generate truncated Bid (tBID). tBid
protein triggers mitochondrial outer membrane permeabilization
by promoting oligomerization of the pro-apoptotic Bcl-2 family
proteins Bak and/or Bax within this membrane. Mitochondrial
outer membrane permeabilization results in egress of proapoptotic proteins from the mitochondrial intermembrane space
(i.e., cytochrome c, Smac/DIABLO, HtrA2, AIF, and endonuclease G), which culminates in the mitochondrial pathway of
PLoS ONE | www.plosone.org
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unclear how up-regulation of DR4 alone could overcome the Mcl1 blockade of the mitochondrial pathway of apoptosis. In this
study, we have demonstrated that down-regulation of XIAP by
Hedgehog inhibition converts Type II TRAIL signaling to a Type
I pathway. Thus, our data define a mechanism by which
Hedgehog signaling modulates TRAIL-induced cell death in
cancer cells and suggest inhibition of this cascade as potential
therapeutic approach for TRAIL-resistant neoplasms..

Primary antisera were those raised to actin, Bcl-2, Bcl-x, Mcl-1, and
Smoothened (Santa Cruz Biotechnology, Santa Cruz, CA: C11,
B19, S18, S19, and H-300, respectively), Bid and cIAP-1 (R&D
Systems, Minneapolis, MN), Bim and XIAP (BD Biosciences, San
Jose, CA), and c-IAP2 (Novus Biologicals, Littleton, CO). For
quantitation of XIAP protein by immunoblot, films were analyzed
by densitometry and the relative signal intensity of the XIAP signal
was normalized to actin in three separate experiments.

Materials and Methods

Apoptosis
Apoptosis was quantified morphologically by staining the nuclei
with 49,6-diamino-2-phenylindole dihydrochloride (DAPI). The
characteristic nuclear changes of apoptosis (i.e. chromatin
condensation and nuclear fragmentation) were assessed by
fluorescence microscopy using excitation and emission wavelengths of 380 and 430 nm, respectively. Caspase-3/7 activity in
cell cultures was employed to assess apoptosis biochemically and
was measured by quantifying fluorophore release from the
caspase-3/7 substrate using the Apo-ONETM homogeneous
caspase-3/7 kit (Promega, Madison, WI).

Ethics Statement
The Mayo Clinic IRB Committee reviewed and approved for
human studies the the protocol entitled ‘‘Genome expression
analysis of human cholangiocarcinoma (CCC).’’ The committee
determined that this constitutes minimal risk research. Data were
analyzed anonymously.

Cell Culture
The human cholangiocarcinoma cell lines, KMCH, HuCCT-1,
and Mz-ChA-1, were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum,
100,000 units/L penicillin, 100 mg/L streptomycin and 100 mg/
L gentamicin as previously described [20,21].

RNA interference
A specific double-stranded 21-nucleotide RNA sequence
complementary to the target message was used to silence human
cIAP-1, XIAP, Bak or Bax expression. Validated siRNAs targeting
cIAP-1 or XIAP were purchased from Santa Cruz Biotechnology.
siRNAs targeting Bak or Bax were designed and synthesized using
the software available at www.ambion.com and the Silencer
siRNA Construction kit from Ambion (Austin, TX). The siRNA
sequences employed to inhibit Bak or Bax expression were as
follows: Bak, 59-AAG TAC GAA GAT TCT TCA AAT CCT
GTC TC-39; Bax, 59-AAG ACG AAC TGG ACA GTA ACA
CCT GTC TC-39 (partial T7-promoter sequence is bold). As a
control, cells were transfected with a scrambled RNA duplex with
the following sequence: 59-AAC GTG ATT TAT GTC ACC
AGA-39. Briefly, cells grown in 6-well dishes were transiently
transfected with 30 nM siRNA using 5 mL/mL siPORTTM
NeoFXTM (Ambion Inc.). Target protein expression was assessed
by immunoblot analysis after transfection with the siRNA.
Short hairpin RNA (shRNA) for Bid was from Sigma Aldrich
[MISSION short hairpin RNA lentiviral plasmid, targeting
Nucleotides 376-396, Genebank accession #NM_001196]. To
generate the Bim targeted shRNA construct, the pSSH1 plasmid
containing the human H1 promoter for the expression of shRNA
was employed. A double-stranded DNA template (59-GAT CCC
CGC AAT AGG CTT TAG GAA AAT TCA AGA GAT TTT
CCT AAA GCC TAT TGC TTT TTG GAA A-39) was inserted
into the pSSH1 plasmid after the H1 RNA promoter. The DNA
insert contains sense and antisense sequences (Bold type) for the
Bim mRNA and a 9-nucleotide linker sequence, yielding
transcription of a shRNA targeting Bim. For stable transfection,
KMCH cells were transfected using OPTI-MEM I (GIBCOInvitrogen, Carlsbad, CA) containing 5 mL/mL LipofectAMINE
2000 (Invitrogen), and 3 mg/mL plasmid DNA. Forty-eight hours
after transfection, fresh medium containing 2 mg/mL puromycin
was added for shRNA plasmid targeting Bid or 1.2 g/L neomycin
was added for shRNA plasmid targeting Bim. Surviving clones
were separated using cloning rings and were individually cultured.
Lentiviral particles containing shRNA to SMO were constructed
using the BLOCK-iT Inducible H1 Lentiviral RNAi System
(Invitrogen), following the manufacturer’s protocol. Sequences
(inserted into pLenti4/BLOCK-iT-DEST) were depicted as
previously described by us [19]. For stable transfection, fresh
medium containing 10 mg/mL Blasticidine-S and 500 mg/mL

Quantitative reverse-transcription polymerase chain
reaction (RT-PCR)
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen, Carlsbad, CA), and cDNA was prepared using random
primers and Moloney murine leukemia virus reverse transcriptase as
previously described in detail [22]. The cDNA product was amplified
by PCR with Taq DNA polymerase using standard protocols. PCR
primers are depicted in Table 1. Primers for 18S ribosomal RNA
(rRNA) were purchased from Ambion Inc. (Austin, TX). Real-time
PCR was performed with the Roche LightCycler using SYBR green
as the fluorophore as previously described [20]. The copy number of
the target mRNA in each sample was normalized as a ratio using the
copy number for 18S rRNA in the denominator.

Immunoblot Analysis
Whole-cell lysates were obtained as previously described by us in
detail [21]. Protein samples were resolved by SDS-PAGE gels,
transferred to nitrocellulose membranes, and blotted with the
indicated primary antibodies at a dilution of 1:500 to 1:1,000.
Peroxidase-conjugated secondary antibodies (Biosource International, Camarillo, CA) were incubated at a dilution of 1:3,000 to
1:5,000. Bound antibodies were visualized using enhanced
chemiluminescence reagents (Amersham, Arlington Heights, IL)
and Kodak X-OMAT film (Eastman Kodak, Rochester, NY).
Table 1. Sequences for real-time PCR primers.

Gene

Primer pair

cIAP-1

59-AGCTAGTCTGGGATCCACCTC-39
59-GGGGTTAGTCCTCGATGAAG-39

cIAP-2

59-TGGAAGCTACCTCTCAGCCTAC-39
59-GGAACTTCTCATCAAGGCAGA-39

XIAP

59-GATGCTGTGAGTTCTGATAGG-39
59-CTTAATGTCCTTGAAACTGAAC-39

doi:10.1371/journal.pone.0018330.t001
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Figure 1. Smoothened inhibition down-regulates both cIAP-1 and XIAP expression. A, Cell lysates from KMCH cells treated with
cyclopamine (5 mM) for the indicated times were immunoblotted for cIAP-1, cIAP-2 and XIAP. Actin was used as a loading control. B, KMCH cells were
transfected with a tetracycline-inducible shRNA expression vector targeting Smoothened (shSMO) or a scrambled shRNA vector; shRNA expression
was induced for 48 hours by treatment with tetracycline (1 mg/mL) followed by immunoblotting for cIAP-1, cIAP-2 and XIAP using whole cell lysates.
C, Cells were treated with vehicle, cyclopamine (5 mM) for 24 hours, or transfected with shSMO as in panel B, then analyzed by real-time RT-PCR for
cIAP-1, cIAP-2 and XIAP using total RNA. D, Total RNA from tissue samples of either cholangiocarcinoma (CCA) or adjacent benign liver was used to
assess XIAP, cIAP-1, and cIAP-2 mRNA expression, normalized to 18S and expressed as fold change from benign. Mean 6 SEM, *p,0.05; **p,0.01;
***p,0.001 compared to vehicle.
doi:10.1371/journal.pone.0018330.g001

Zeocin (Invitrogen) was added to cells 48 hours after transduction.
Surviving clones were separated using cloning rings and were
individually cultured. Expression was induced with 1 mg/ml
tetracycline (Sigma-Aldrich, St. Louis, MO). After an additional
48 hours cells were used for experiments. Target suppression was
assessed by immunoblot analysis.

sulfonyl fluoride, 0.4 mM dithiothreitol, 0.5 mg/mL poly(dI-dC),
0.5 mg/mL salmon sperm) with 0.04 pmol of Cy5.5-labeled
double-stranded DNA oligonucleotide (synthesized by the Mayo
Clinic Advanced Genomics Technology Core, Rochester MN)
containing the wild-type putative GLI binding sequences within
the promoter region of human XIAP gene. Protein-DNA
complexes were separated from the unbound DNA probe by
electrophoresis through 5% native polyacrylamide gels containing
0.5X Tris borate-EDTA. Fluorescence was visualized directly on
the gel using an Odyssey fluorescent imager (Licor Biosciences,
Lincoln, NE). For competition assays, a 200-fold molar excess of
unlabeled double-stranded oligonucleotide was added to the
reaction mixture 20 min before the addition of the fluorescent
probe.

Electrophoretic mobility shift assay (EMSA)
Nuclear cell extracts were prepared using NE-PER nuclear and
cytoplasmic extraction reagents (Pierce, Rockford, IL) according to
the manufacturer’s instructions. For the EMSA, 20 mg of nuclear
proteins were incubated at room temperature for 20 min in
binding buffer (25 mM HEPES, pH 7.5, 0.1 M NaCl, 2 mM
EDTA, 6% glycerol, 0.1% Triton X-100, 0.1 mM phenylmethylPLoS ONE | www.plosone.org
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Figure 2. XIAP promoter predicted GLI-binding sites exhibit sequence-specific binding to nuclear proteins. A, Putative GLI binding sites
in the XIAP promoter region. Nucleotide positions were counted from the transcription start site (TSS). Potential binding sites were observed as indicated
by arrows on the schematic (I and II). B, Nuclear protein extracts were isolated from KMCH cells. EMSA was performed using Cy5.5-labeled doublestranded oligonucleotides containing the putative GLI binding sequences within the human XIAP promoter, and competition experiments with 200-fold
molar excess cold oligonucleotides as described under ‘‘MATERIALS AND METHODS’’. C, Total cellular protein was isolated 48 hours after transient
transfection with the indicated siRNA against GLI family members. XIAP protein expression was determined by immunoblotting and the signal was
quantified by densitometry as a ratio to actin expression. D, Chromatin immunoprecipitation using antiserum to GLI1, GLI2, GLI3, or a control IgG was
performed followed by PCR using primers flanking site I (341 bp) within the XIAP promoter region, as indicated. As a positive control, ChIP was
performed using primers flanking the Bcl-2 promoter GLI-binding site (GLI1 and GLI2), or primers flanking the GLI3 binding site within the GLI1 promoter.
doi:10.1371/journal.pone.0018330.g002

Chromatin Immunoprecipitation

Materials

ChIP was performed from KMCH cells treated with 250 nM
recombinant Sonic Hedgehog for 5 hours using total cellular DNA
sheared to ,500 bp fragments, using ExactaCHIP chromatin
immunoprecipitation kit (R&D systems) following manufacturer’s
instructions and samples were pre-cleared using agarose beads plus
salmon sperm slurry (Upstate, Lake Placid, NY) prior to
immunoprecipitation. Positive control primers supplied by the
manufacturer were for the Bcl-2 promoter (bound by GLI1 and
GLI2) and the GLI1 promoter (bound by GLI3). Primers for XIAP
promoter site I were, Forw: 59 TTACTGCAGCCTCCAACTCC;
Rev: 59 CATCTCTCCATGCTCTGAACTC.

Reagents were purchased from the following suppliers: DAPI
was from Sigma; recombinant human TRAIL and recombinant
Sonic Hedgehog were from R&D Systems; anti-human Fas
antibody (CH-11) was from MBL International (Nagoya, Japan);
cyclopamine was from LC Laboratories (Woburn, MA).

Results
Smoothened inhibition down-regulates cIAP-1 and XIAP
expression
Given a pivotal mechanistic role for inhibitor of apoptosis
proteins (IAPs) in death receptor signaling [23] and the role
Hedgehog in cellular survival, we first ascertained if inhibiting
Smoothened (SMO), the signaling component of the Hedgehog
receptor complex, modulates expression of IAPs. Treatment with
cyclopamine, a well-established pharmacological inhibitor of

Statistical Analysis
All data represent at least three independent experiments and
are expressed as mean 6 SE. Differences between groups were
compared using ANOVA with Bonferroni post hoc correction.
PLoS ONE | www.plosone.org
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Figure 3. Cyclopamine sensitizes cells to TRAIL-induced cell death despite knockdown of Bid or Bim. A, Immunoblot analysis was
performed on whole cell lysates obtained from KMCH cells stably transfected with the specific shRNA targeting Bid or Bim, using indicated antisera.
Actin was used as a loading control. B, KMCH cells stably transfected with Bid- or Bim-shRNA and untransfected parental KMCH cells were treated
with Fas agonistic antibody CH-11 (100 mg/mL) for 5 hours followed by DAPI staining. Cells with apoptotic morphology were counted. Mean 6 SEM,
***p,0.001 compared to parental cells treated with CH-11. C, In parallel, caspase-3/7 activity was measured in cells treated as in panel B. Mean 6
SEM, ***p,0.001. D, KMCH cells stably transfected with Bid- or Bim-shRNA were pretreated with vehicle or cyclopamine (5 mM) for 24 hours, and then
treated with TRAIL (5 ng/mL) for 5 hours followed by DAPI staining. Cells with apoptotic morphology were counted. Mean 6 SEM, ***p,0.001
compared to cells treated with TRAIL alone. E, KMCH stable cell lines were treated as in panel D, and after 5 hours caspase-3/7 activity was measured.
Mean 6 SEM, ***p,0.001 compared to cells treated with TRAIL alone. F, Whole cell lysates from KMCH, HuCCT-1, and Mz-ChA-1 cells treated with
vehicle or cyclopamine (5 mM) for 24 hours were analyzed by immunoblot using anti-Bcl-2, Mcl-1, or Bcl-x antisera. Actin was used as a loading
control. G, Whole cell lysates were obtained from shBid-, shBim- and untransfected parental KMCH cells treated with vehicle or cyclopamine (5 mM)
for 24 hours and were analyzed by immunoblot using anti-Bcl-2, Mcl-1, or Bcl-x antisera. Actin was used as a loading control.
doi:10.1371/journal.pone.0018330.g003

SMO [24,25], decreased cellular IAP-1 (cIAP-1) and X-linked IAP
(XIAP) protein levels, but had no effect on cIAP-2 protein
expression. The down-regulation of XIAP was more rapid,
occurring within 4 hours, whereas loss of cIAP-1 protein occurred
only after 24 hours (Fig. 1A). The pharmacological effect of
cyclopamine was validated by using shRNA targeted knockdown
of SMO, a signaling component of the Hedgehog receptor, which
also decreased both cIAP-1 and XIAP cellular protein levels, but
not cIAP-2 (Fig. 1B). To determine if SMO inhibition affected
mRNA levels or acted exclusively post-transcriptionally, cIAP-1,
PLoS ONE | www.plosone.org

cIAP-2, and XIAP mRNA expression was determined after
cyclopamine treatment or shRNA to SMO. Both XIAP and
cIAP-1 mRNA levels were decreased by SMO inhibition (Fig. 1C).
The clinical relevance of IAP regulation was assessed in tumor and
adjacent benign samples from patients with cholangiocarcinoma.
A two-fold increase in XIAP mRNA levels was observed in tumor
tissue (Fig. 1D). The levels of cIAP-1 and -2 were not significantly
different. That cIAP-1 is not elevated in tumor samples despite
regulation by Hedgehog (Fig. 1C) may indicate additional as-yetunknown factors also contribute to control of IAP expression in the
5
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Figure 4. Cyclopamine sensitizes cells to TRAIL-induced cell death independent of Bax and Bak. A, Whole cell lysates from KMCH cells
transiently transfected with specific siRNA targeting Bax and/or Bak or scrambled siRNA were obtained 48 hours after transfection and analyzed by
immunoblot using anti-Bax or anti-Bak antisera. Actin was used as a loading control. B, KMCH cells transiently transfected with Bax- and Bak-siRNA or
scrambled siRNA were pretreated (24 hours) with medium or cyclopamine (5 mM) as indicated, then treated with Fas agonistic antibody CH-11
(100 mg/mL) for 5 hours. Cells with apoptotic nuclear morphology were counted. Mean +/2 SEM; ***p,0.001. C, KMCH cells were treated as in panel
B and caspase-3/7 activity was measured after 5 hours. Mean +/2 SEM; ***p,0.001 D, KMCH cells transiently transfected with Bax- and Bak-siRNA or
scrambled siRNA were pretreated with vehicle or cyclopamine (5 mM) for 24 hours, and then treated with TRAIL (5 ng/mL) for 5 hours. Cells with
apoptotic nuclear morphology were counted. Mean 6 SEM, #p,0.05 and ***p,0.001 compared to cells transfected with scrambled siRNA and
treated with TRAIL. E, KMCH cells transiently transfected with indicated siRNA and treated as in panel D, were assayed after 5 hours for caspase-3/7
activity. Mean 6 SEM; ***p,0.001.
doi:10.1371/journal.pone.0018330.g004

tumor. These data suggest the Hedgehog signaling pathway
regulates cIAP-1 and XIAP expression, but that only XIAP levels
are elevated in clinical samples. Therefore, we largely focused on
XIAP for the remainder of our studies.

promising candidate GLI-binding sites (Fig. 2A) were identified
upstream of the XIAP transcription start site (NM_001167) at
positions 22820/22807 (Site I) and 21594/21581 (Site II). Each
had two mismatches as compared to the consensus sequence [26];
Site I is identical to the validated 9-nucleotide Bcl-2 GLI-binding
site, Bs1 [27], while Site II is identical to the confirmed DR4 GLIbinding site [19]. We performed electrophoretic mobility shift
assay experiments. Binding to both putative GLI binding
sequences was observed in nuclear extracts from KMCH cells.
The mobility shift of CY 5.5-labeled probe could be prevented by
adding a 200-fold molar excess of the unlabeled probe

GLI2 binds to the XIAP promoter and regulates its
expression
To determine if XIAP is transcriptionally regulated by
Hedgehog-responsive GLI transcription factors, we searched the
5 Kb 59-flanking region of the human XIAP gene for the 59GACCACCCAXXXXG -39 GLI consensus binding motif. Two
PLoS ONE | www.plosone.org
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(Competitor; Fig. 2B). Of the three GLI family members, siRNA
to GLI2 caused a significant decrease in XIAP protein expression
while siRNA to GLI1 or GLI3 did not alter XIAP levels (Fig. 2C).
To ascertain if GLIs bind to the XIAP promoter, we performed
chromatin immunoprecipitation experiments to assess occupation
of the endogenous XIAP promoter using antibodies to GLI1,
GLI2, and GLI3. Binding of GLI2 was observed using primers
that amplify Site I (Fig. 2D). Control IgG did not yield a product,
demonstrating specificity of the antisera used, and positive-control
promoter sites demonstrated the expected occupation by GLI1
and GLI2 (Bcl-2 promoter), and GLI3 (GLI1 promoter). These
data suggest that Hedgehog directly regulates XIAP expression by
GLI2 transcription factor binding to Site I in the XIAP promoter.

Sensitization by Hedgehog inhibition is independent of
mitochondrial apoptotic mediators, Bid/Bim or Bax/Bak
XIAP is a key discriminator for converting Type II to Type I
death receptor signaling [9], thus, we considered loss of XIAP
protein as a mechanism by which Hedgehog inhibition sensitized
cholangiocarcinoma cells to TRAIL-induced apoptosis. Bid and
Bim are key signaling intermediates in Type II proapoptotic death
receptor signaling [28,29]. Based on this information, we next
ascertained if Hedgehog inhibition sensitized cells to TRAIL
cytotoxicity in the absence of Bid or Bim. shRNA constructs
targeting Bid and Bim efficiently knocked down the respective
cellular protein levels (Fig. 3A). The near complete silencing of Bid
or Bim protein levels was functionally confirmed by taking
advantage of the observation that Fas Type II death receptor
signaling is dependent upon Bid or Bim [30]. Indeed, Bid or Bim
knockdown was sufficient to inhibit Fas-induced cell death by the
agonistic antibody CH-11 (Fig. 3B and 3C), a classic Type II
pathway of cell death [31]. Thus, if TRAIL-induced cell death in
cyclopamine-sensitized cells was dependent on Type II signaling,
then Bid or Bim silencing should similarly protect from TRAIL
cytotoxicity. However, despite the absence of Bid or Bim, the
Hedgehog inhibitor cyclopamine still sensitized human cholangiocarcinoma cells to TRAIL-induced cell death (Fig. 3D and 3E).
Because an imbalance between anti- and proapoptotic Bcl-2
family proteins by cyclopamine could explain its effects on
sensitizing cells to TRAIL killing, we profiled this class of proteins
by immunoblot analysis. Bcl-xL protein expression was significantly lower in KMCH cells than HuCCT-1 or Mz-ChA-1 cells,
but none of the three antiapoptotic proteins (Bcl-2, Mcl-1, or BclxL) was altered by cyclopamine treatment (Fig. 3F). Cyclopamine
also did not alter cellular protein levels of the antiapoptotic Bcl-2
family proteins in KMCH cells stably transfected with shRNA
targeting Bid or Bim (Fig. 3G). Likewise, SMO inhibition does not
alter BH3-only proteins or pro-apoptotic Bcl-2 family proteins,
Bax and Bak [19]. Taken together, these data suggest that
inhibition of the Hedgehog pathway sensitizes human cholangiocarcinoma cells to TRAIL cytotoxicity by a process independent of
Bid or Bim or alterations in the expression of multidomain Bcl-2
family proteins. The independence of Bid or Bim suggested the
intriguing possibility that cyclopamine may sensitize cholangiocarcinoma cells to TRAIL by converting apoptotic signaling from
a Type II to a Type I death receptor pathway.
To test this hypothesis, we next determined whether Hedgehog
inhibition converts Type II death receptor signaling to Type I
signaling. The sine qua non of Type I death receptor signaling is
its lack of dependence on Bax and Bak [32]. Efficient knockdown
of Bax and Bak protein levels was achieved by siRNA targeting
(Fig. 4A). Targeted knockdown of Bax plus Bak protein functioned
to inhibit Fas-mediated apoptosis by CH-11 (Fig. 4B and 4C),
consistent with Type II signaling. TRAIL alone had a small
PLoS ONE | www.plosone.org

Figure 5. Knockdown of XIAP sensitizes human cholangiocarcinoma cells to TRAIL cytotoxicity. KMCH cells were transfected
with scrambled siRNA or specific siRNA for cIAP-1 or XIAP. A, Whole cell
lysates were prepared for immunoblotting from KMCH cells 48 hours
after siRNA transfection. B, Forty-eight hours after transfection as in
panel A, cells were treated with human recombinant TRAIL (5 ng/mL) or
medium for 5 hours. Cells were then stained with DAPI and cells with
apoptotic nuclear morphology were counted and expressed as a
percentage of total nuclei. C, In parallel, cells were transfected and
treated with TRAIL as in panel B, and after 5 hours caspase-3/7 activity
was measured. Mean 6 SEM, *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0018330.g005

apoptotic effect on KMCH cells that was efficiently blocked by
Bax/Bak silencing, indicating that TRAIL normally kills cholangiocarcinoma cells by the Type II pathway (Fig. 4D). However,
TRAIL-induced apoptosis was dramatically increased by cyclopamine (Fig. 4D and 4E). The increased apoptosis was completely
(Fig. 4E) or nearly completely (Fig. 4D) insensitive to Bax/Bak
silencing. These data suggest that Hedgehog inhibition circumvents mitochondrial resistance to TRAIL cytotoxicity by converting a Type II signaling to a Type I signaling pathway.

Knockdown of XIAP sensitized cholangiocarcinoma cells
to TRAIL-induced apoptosis despite inhibition of Bid
Next, we determined the functional relevance of XIAP expression
in these cancer cells using siRNA-targeted knockdown of cIAP-1 or
7
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appropriate, BI6C9 remained in the medium during TRAIL treatment).
Cells with apoptotic nuclear morphology were quantified. Mean 6 SEM,
*p,0.05; n.s. indicates p.0.10 by ANOVA with Bonferroni correction.
doi:10.1371/journal.pone.0018330.g006

XIAP. Efficient targeting of cIAP-1 and XIAP protein expression was
confirmed by immunoblot analysis (Fig. 5A). Consistent with previous
reports [33,34,35,36], knockdown of XIAP significantly sensitized the
cells to TRAIL cytotoxicity, while knockdown of cIAP-1 only
modestly sensitized the cells to TRAIL-induced cell death, measured
either morphologically (Fig. 5B) or biochemically (Fig. 5C). Thus,
regulation of XIAP expression is a potential mechanism by which
Hedgehog signaling prevents TRAIL cytotoxicity.
The above data are consistent with a switch from Type II to
Type I receptor-mediated apoptosis by SMO inhibition; SMO
inhibition appears to mediate this switch by down-regulating XIAP
gene expression. To test this interpretation of the data, we
designed experiments to ascertain if knockdown of XIAP protein
was sufficient to convert TRAIL signaling to a mitochondriaindependent, Type I pathway. We employed a small molecule
inhibitor of Bid, BI-6C9, to circumvent mitochondria-dependent
cell death [37]. First, to confirm that BI-6C9 functionally inhibited
cell death in this system, KMCH cells were pre-treated with BI6C9 or vehicle (DMSO), followed by Fas agonistic antibody.
Indeed, pharmacologic inhibition of Bid by BI-6C9 was sufficient
to repress Fas-induced apoptosis. Again, SMO inhibition did not
affect apoptosis by CH-11 treatment (Fig. 6A). In contrast, BI-6C9
did not functionally inhibit TRAIL-induced cell death in
cyclopamine-treated cells (Fig. 6B). Importantly, siRNA directed
against XIAP also sensitized cells to TRAIL-induced apoptosis,
and BI-6C9 did not mitigate cell death (Fig. 6C). Thus, SMO
inhibition, by decreasing cellular XIAP protein levels, converts
Type II TRAIL death receptor signaling to a Type I pathway; an
effect recapitulated by siRNA targeted knockdown of XIAP.

Discussion
Results of the present study provide new insights into the
mechanisms by which the Hedgehog pathway inhibits TRAIL
cytotoxicity. The results demonstrate that in human cholangiocarcinoma cells, (i) Hedgehog pathway inhibition sensitizes human
cholangiocarcinoma cells to TRAIL-mediated apoptosis, in part,
by down-regulating XIAP protein; (ii) XIAP repression by SMO
inhibition occurs at the mRNA level as well, consistent with GLImediated enhancement of XIAP transcription; and (iii) inhibition
of Hedgehog promotes TRAIL cytotoxicity independent of Bid,
Bim, Bax, and Bak. These data suggest inhibition of Hedgehog
signaling modulates TRAIL cytotoxicity in human cholangiocarcinoma cells by regulating XIAP expression and converting
TRAIL signaling from Type II to Type I apoptotic signaling. Each
of these results is discussed in greater detail below.
Hedgehog signaling components are constitutively expressed by
cholangiocarcinoma cells [19,38]. Indeed, this pathway is active in
human cholangiocarcinoma cell lines in an autocrine and/or
paracrine manner as cyclopamine suppresses the growth of
cholangiocarcinoma cells both in vitro and in vivo [38] and imparts
survival signals [19]. Our current study extends these observations by
suggesting Hedgehog oncogenic signaling regulates a non-mitochondrial pathway of apoptosis. Indeed, despite inhibiting TRAIL
cytotoxicity, Hedgehog does not appear to alter expression of
antiapoptotic Bcl-2 family proteins which govern the mitochondrial
cell death pathway. Instead, Hedgehog appears to suppress expression
of the TRAIL receptor DR4 [19] and promotes expression of XIAP,
which work in concert to reduce TRAIL cytotoxicity.

Figure 6. XIAP knockdown sensitizes cells to TRAIL-induced
cell death despite Bid inhibition. A, KMCH cells were incubated for
24 hours in medium or cyclopamine (5 mM) followed by treatment with
either vehicle (DMSO, final concentration 0.1% v/v) or the Bid inhibitor,
BI-6C9 (10 mM) for 1 hour. Cells were subsequently treated with Fas
agonistic antibody CH-11 (100 mg/mL) for an additional 5 hours (where
appropriate, BI-6C9 remained in the medium during CH-11 treatment).
Cells with apoptotic nuclear morphology were quantified as referenced
in the Materials and Methods. Mean +/2 SEM; ***p,0.001; n.s. indicates
p.0.10 by ANOVA with Bonferroni correction. B, KMCH cells were
incubated overnight with or without cyclopamine followed by BI-6C9 as
in panel A, except that apoptosis was induced by TRAIL (5 ng/mL) for
5 hours (where appropriate, BI-6C9 remained in the medium during
TRAIL treatment) and apoptotic nuclear morphology was quantified.
Mean +/2 SEM; ***p,0.001; n.s. indicates p.0.10 by ANOVA with
Bonferroni correction. C, KMCH cells transiently transfected with XIAP
siRNA or scrambled siRNA (48 hours) were pretreated with BI-6C9
(10 mM) or DMSO vehicle (final concentration 0.1% v/v) for 1 hour. Next,
the cells were treated with TRAIL (5 ng/mL) for 5 hours (where
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cancer, as XIAP inhibition similarly restored TRAIL sensitivity by
converting cytotoxic signaling from a Type II to a Type I death
receptor pathway in several TRAIL-resistant cancer cell lines
[33,34,35]. Our investigation confirms that XIAP inhibition can
switch to mitochondria-independent death receptor signaling and
integrates this observation into the protective effects of constitutive
Hedgehog signaling observed in cholangiocarcinoma cells. A
schematic illustration of the interaction of TRAIL signaling and
SMO inhibition is presented in Figure 7. Based on the results of the
current study, as well as current concepts in death receptor signaling,
we propose that blocking constitutive Hedgehog signaling via SMO
inhibitors increases DR4 mRNA and protein levels [19] as well as
inhibiting XIAP expression. This combined action sensitizes cells to
TRAIL killing by the Type I death receptor pathway, bypassing the
Mcl-1 mediated block in Type II TRAIL killing.
Of note, cyclopamine did not convert Fas signaling to a Type I
pathway, suggesting differential signaling pathways for these two
death receptors. We speculate that Fas signaling and TRAIL
signaling are affected differently by Hedgehog inhibition. Specifically,
cholangiocarcinoma cells are sensitive to Fas-agonist induced killing
at baseline in contrast to TRAIL, and while cyclopamine sensitized
cells to TRAIL killing, it did not alter Fas-agonist sensitivity. Further,
Hedgehog inhibition did not alter Fas protein expression, but
increased DR4 at both the mRNA and protein levels [19].
Potentially, the combined effects of decreasing cellular XIAP protein
levels plus enhancing DR4 expression by Hedgehog inhibition may
explain this differential regulation of death ligand signaling.
In conclusion, our study implicates Hedgehog stimulation of
XIAP expression as a mechanism for TRAIL resistance in human
cholangiocarcinoma cells. As these cancers express TRAIL in vivo,
pharmacologic inhibition of Hedgehog signaling may promote
autocrine and/or paracrine cholangiocarcinoma-autonomous
cytotoxicity. Collectively, these concepts suggest Hedgehog
pathway inhibitors, which are currently in clinical development
[39,40], may have therapeutic efficacy in the treatment of human
cholangiocarcinoma.

Figure 7. SMO inhibition sensitizes cells to TRAIL-induced
apoptosis by increasing DR4 and decreasing XIAP protein
levels, thereby switching cells from Type II to Type I death
receptor signaling. Schematic illustration of the interaction of
Hedgehog and TRAIL signaling in cholangiocarcinoma cells. Death
signaling upon TRAIL binding to DR4 normally is dependent on
mitochondrial dysfunction (induced by Bid/Bim as well as Bak/Bax
activation) to induce cholangiocarcinoma cell death (Type II pathway), a
pathway blocked by elevated Mcl-1 protein levels in cholangiocarcinoma cells. Alternately, following DR4 ligation, robust caspase 3
activation can induce Type I death signaling, a pathway inhibited by
XIAP expression under normal conditions. Inhibition of SMO expression
or activity sensitizes cells to TRAIL via increasing DR4 [19] and
decreasing XIAP levels, thereby switching cells from Type II to Type I
death receptor signaling and promoting apoptosis.
doi:10.1371/journal.pone.0018330.g007

Cholangiocarcinoma cells express robust amounts of antiapoptotic
Bcl-2 family proteins, in particular Mcl-1, which mitigates TRAIL
cytotoxicity [14,15], consistent with a mitochondria-dependent, Type
II death receptor signal. In contrast, we found that SMO inhibition
sensitized cholangiocarcinoma cells to TRAIL even after depletion of
Bid, Bim, Bax, or Bak by specific siRNA, suggesting mitochondrial
dysfunction is not required for TRAIL killing in this model. Finally,
genetic inhibition of XIAP not only sensitized cholangiocarcinoma
cells to TRAIL killing, but did so independently of mitochondrial
involvement (i.e. in the presence or absence of Bid inhibition). The
degree of sensitization to TRAIL by XIAP siRNA was less than that
seen by SMO inhibition (c.f. Fig. 6B and 6C), indicating that
cyclopamine likely affects additional targets to fully sensitize cells to
apoptosis. One plausible candidate is the TRAIL receptor DR4 [19].
Recent reports suggest XIAP may have a similar role in pancreatic
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